tiprankstipranks
Merrimack Pharmaceuticals Inc. (MACK)
NASDAQ:MACK
US Market

Merrimack Pharmaceuticals (MACK) Financial Statements

354 Followers

Merrimack Pharmaceuticals Financial Overview

Merrimack Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-0.082; its P/E ratio is -178.21; Merrimack Pharmaceuticals is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ 50.00K$ -279.00K$ -391.00K$ -271.00K$ -607.00K
EBITDA$ -83.00K$ -418.00K$ -417.00K$ -271.00K$ -607.00K
Net Income Common Stockholders$ 38.00K$ -279.00K$ -391.00K$ -271.00K$ -492.00K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 18.88M$ 18.90M$ 18.97M$ 19.40M$ 19.44M
Total Assets$ 19.19M$ 19.30M$ 19.45M$ 19.64M$ 19.84M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -18.88M$ -18.90M$ -18.97M$ -19.40M$ -19.44M
Total Liabilities$ 441.00K$ 493.00K$ 411.00K$ 463.00K$ 589.00K
Stockholders Equity$ 18.75M$ 18.81M$ 19.04M$ 19.17M$ 19.28M
Cash Flow-
Free Cash Flow$ -300.00K$ -200.00K$ -624.00K$ -400.00K$ -185.00K
Operating Cash Flow$ -300.00K$ -200.00K$ -624.00K$ -400.00K$ -185.00K
Investing Cash Flow$ 68.00K$ -3.85M$ -8.81M$ 139.00K-
Financing Cash Flow$ 133.00K-$ 209.00K$ 179.00K$ 6.53M
Currency in USD

Merrimack Pharmaceuticals Earnings and Revenue History

Merrimack Pharmaceuticals Debt to Assets

Merrimack Pharmaceuticals Cash Flow

Merrimack Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis